Temodar Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
Conditions:   Glioblastoma, IDH-wildtype;   Glioblastoma;   Glioblastoma Multiforme;   Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype;   GBM Interventions:   Drug: Eflornithine (Dose Level 1);   Drug: Eflornithine (Dose Level 2);   Drug: Eflornithine (Dose Level -1);   Drug: Temozolomide Sponsor:   Orbus Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials

The Efficacy and Safety of Temozolomide in Patients With MPPGL
Conditions:   Pheochromocytoma, Metastatic;   Paraganglioma, Malignant;   Pheochromocytoma Malignant Intervention:   Drug: Temozolomide capsule Sponsor:   Peking Union Medical College Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 15, 2023 Category: Research Source Type: clinical trials